ReviewSpringer seminars in immunopathology2005
Mannan-binding-lectin-associated serine proteases, characteristics and disease associations.
Review in Springer seminars in immunopathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 132 citations in OpenAlex.
- Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin.Journal of clinical immunology · 2006Trial
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Increased levels of ficolin-1 and of C3dg are independently associated with high risk of infection in patients with chronic kidney disease: a prospective cohort study.Frontiers in immunology · 2025Article
- Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.International journal of molecular sciences · 2022Review
- Activity of Mannose-Binding Lectin on Bacterial-Infected Chickens-A Review.Animals : an open access journal from MDPI · 2021Review
- MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19.Genetics and molecular biology · 2021Article
- Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway.Journal of clinical immunology · 2020Article
- Tuberculosis, onychomycosis and immune deficiency in complicated Crohn's disease.BMJ case reports · 2019Article
- Substitution of Mannan-Binding Lectin (MBL)-Deficient Serum With Recombinant MBL Results in the Formation of New MBL/MBL-Associated Serine Protease Complexes.Frontiers in immunology · 2018Article
- Impact of MBL and MASP-2 gene polymorphism and its interaction on susceptibility to tuberculosis.BMC infectious diseases · 2015Article
- Deficiency in mannose-binding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection.The American journal of tropical medicine and hygiene · 2015Article
- The lectin pathway of complement and rheumatic heart disease.Frontiers in pediatrics · 2014Review
- Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.Clinical reviews in allergy & immunology · 2013Review
- Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity.Mammalian genome : official journal of the International Mammalian Genome Society · 2013Article
- The serine protease domain of MASP-3: enzymatic properties and crystal structure in complex with ecotin.PloS one · 2013Article
- CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.Clinical & developmental immunology · 2013Review
- Mannan-binding lectin in cerebrospinal fluid: a leptomeningeal protein.Fluids and barriers of the CNS · 2012Article
- Humoral innate immune response and disease.Clinical immunology (Orlando, Fla.) · 2012Review
- Studies of the pattern recognition molecule H-ficolin: specificity and purification.The Journal of biological chemistry · 2012Article
- Microglia, Alzheimer's disease, and complement.International journal of Alzheimer's disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mannan-binding lectin (MBL)-associated serine proteases (MASPs) circulate in plasma as zymogens in complexes with MBL and with L- and H-ficolin. Upon binding of MBL or ficolin to pathogen-associated molecular patterns, the MASPs are activated. MASP-2 can now cleave C4 and C2 to generate the C3 convertase, C4bC2b. The functions of the other two MASPs, MASP-1 and MASP-3 have not been elucidated. MASP-1 can cleave C2, and with low efficiency also C3, and may serve a function through direct C3 activation. No natural substrate for MASP-3 has been identified. MBL deficiency, occurring at a frequency of about 10%, is the most common congenital immunodeficiency and is associated with susceptibility to infections and autoimmune disorders. Inherited MASP-2 deficiency has been described as the result of a mutation causing the exchange of aspartic acid with a glycine at position 105, a position in the first domain, CUB1, involved in calcium binding. This mutation abolishes the binding to MBL and ficolins, and deprives MASP-2 of functional activity. The index case suffered from recurrent severe infections and autoimmune reactions. The gene frequency of the mutation among Caucasians is 3.6%. It is not found in Chinese, who present a different mutation also associated with MASP-2 deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.